[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:t-cell-histiocyte-rich-large-b-cell-lymphoma:myc-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","MYC Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[26],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z"]